85%Confidence
0Views
FDASource
2026-03-07Date
Summary
Additional sterility issues with ketamine products at Fresenius Kabi's compounding facility suggest systemic quality control problems that could impact mental health treatment availability. This may create opportunities for competitors in the ketamine therapy market while damaging Fresenius's sterile compounding reputation.
Actionable: Evaluate alternative ketamine suppliers for psychiatric and pain management treatment centers.
AI Confidence: 85%
Data Points
firmFresenius Kabi Compounding, LLC
classificationClass II
statusOngoing
distributionUS Nationwide.
productketamine HCl, 1,000 mg, 1,000 mg per 100 mL (10 mg per mL) in Sodium Chloride Injection, Fagron Sterile Services, 20 Dan Road, Canton, MA 02021, NDC 7
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now